Cleveland BioLabs, Inc. (CBLI) Short Interest Down 50.5% in May

Cleveland BioLabs, Inc. (NASDAQ:CBLI) saw a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 247,937 shares, a decrease of 50.5% from the May 15th total of 500,700 shares. Approximately 6.7% of the shares of the company are short sold. Based on an average daily volume of 183,921 shares, the days-to-cover ratio is currently 1.3 days.

Shares of Cleveland BioLabs (NASDAQ CBLI) opened at 3.27 on Friday. The stock’s market capitalization is $36.88 million. The firm has a 50-day moving average of $3.50 and a 200 day moving average of $2.26. Cleveland BioLabs has a 12-month low of $1.22 and a 12-month high of $5.55.

Cleveland BioLabs (NASDAQ:CBLI) last issued its earnings results on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter. The firm had revenue of $0.58 million during the quarter. Cleveland BioLabs had a negative net margin of 111.40% and a negative return on equity of 28.45%. Equities analysts forecast that Cleveland BioLabs will post ($0.16) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/markets/2231145/cleveland-biolabs-inc-cbli-short-interest-down-50-5-in-may.html.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231145/cleveland-biolabs-inc-cbli-short-interest-down-50-5-in-may.html

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.